Osteoprotegerin and the development of myeloma bone disease

Osteoprotegerin and the development of myeloma bone disease

Bibliographic Details
Main Authors:	Croucher, P, Shipman, C, Vanderkerken, K
Format:	Conference item
Published:	2004

Similar Items

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
by: Croucher, P, et al.
Published: (2003)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
by: Croucher, P, et al.
Published: (2001)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
by: Croucher, P, et al.
Published: (2001)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
by: De Leenheer, E, et al.
Published: (2004)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
by: Croucher, P, et al.
Published: (2000)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
by: Shipman, C, et al.
Published: (2002)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
by: Shipman, C, et al.
Published: (2000)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
by: Vanderkerken, K, et al.
Published: (2003)

Bisphosphonates and in vivo models of multiple myeloma - Reply
by: Shipman, C, et al.
Published: (2001)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
by: Shipman, C, et al.
Published: (2002)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
by: De Leenheer, E, et al.
Published: (2002)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
by: Croucher, P, et al.
Published: (2001)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
by: Shipman, C, et al.
Published: (2002)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
by: Shipman, C, et al.
Published: (2003)

Advances in the management of myeloma bone disease.
by: Shipman, C, et al.
Published: (2005)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
by: Croucher, P, et al.
Published: (2002)

Bisphosphonates--mechanisms of action in multiple myeloma.
by: Shipman, C, et al.
Published: (2000)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
by: Croucher, P, et al.
Published: (2002)

Tumor-host cell interactions in the bone disease of myeloma.
by: Fowler, J, et al.
Published: (2011)

Role of osteoprotegerin (OPG) in cancer.
by: Holen, I, et al.
Published: (2006)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
by: Shipman, C, et al.
Published: (2000)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
by: Croucher, P, et al.
Published: (2003)

Dkk1 modulates osteoclastogenesis and bone resorption: Implications for myeloma bone disease.
by: Oyajobi, B, et al.
Published: (2005)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
by: Locklin, R, et al.
Published: (2005)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
by: Mueller, G, et al.
Published: (2004)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
by: Mueller, G, et al.
Published: (2004)

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
by: Eaton, C, et al.
Published: (2004)

The pathogenesis of the bone disease of multiple myeloma.
by: Edwards, C, et al.
Published: (2008)

Lithium inhibits the development of myeloma bone disease in vivo.
by: Edwards, C, et al.
Published: (2006)

The role of osteoprotegerin in breast and prostate cancer
by: Holen, I, et al.
Published: (2002)

Novel therapeutic targets in myeloma bone disease.
by: Webb, S, et al.
Published: (2014)

Anti-tumour activity of bisphosphonates in human myeloma cells.
by: Shipman, C, et al.
Published: (1998)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
by: Holen, I, et al.
Published: (2002)

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
by: Eaton, C, et al.
Published: (2004)

Targeting Wnt signaling in myeloma in vivo; Differential effects on tumor burden and myeloma bone disease
by: Edwards, C, et al.
Published: (2007)

Nitrogen-containing bisphosphonates induce apoptosis in human bone marrow-derived myeloma cells in vitro by inhibiting protein prenylation.
by: Gordon, S, et al.
Published: (1999)

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
by: Shipman, C, et al.
Published: (1997)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
by: Shipman, C, et al.
Published: (2000)

The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
by: Shipman, C, et al.
Published: (1998)

Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment.
by: Locklin, R, et al.
Published: (2007)